FDA approves new Kisunla dosing regimen to lower ARIA-E risk
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
An advisory committee to the U.S. Food and Drug Administration (FDA) unanimously voted in favor of donanemab for early Alzheimer's.| Alzheimer's News Today
